Clade Therapeutics
Cambridge, US · Founded 2020 · Delaware corporation · 7 employees on LinkedIn · 10 known investors
Find your way into Clade Therapeutics
27 people in our graph share verified history with the Clade Therapeutics team — schools, employers, funds. One of them is your warm intro.
Steve Holtzmanunlockedknows Chad A. Cowan · together at Cellular Intelligence (overlapped)
×3knows the team · via Cellular Intelligence
×5knows the team · via The University of Texas Southwestern Medical School
×2knows the team · via Harvard Stem Cell Institute
knows the team · via Clade Therapeutics
Founders & leadership
Clade Therapeutics was founded in 2020 by Chad A. Cowan.
CA
Chad A. CowaninFounder and Chief Executive Officer2020–2024Chad Cowan is an executive at Clade Therapeutics with background in biotech R&D and translational research, including expertise in stem cell research, iPSC cell therapy development, genetic engineering, and genome editing.
LV
Leandro VetcherNamed on SEC filing
DV
Daniel VasellaNamed on SEC filing
JG
Jim GlasheenNamed on SEC filing
NW
Neil WhiteNamed on SEC filing
Board
MM
Martin MurphyBoard director
Investors · 10
SynconaLondon
Bain Capital Life SciencesreportedBoston
Casdin CapitalreportedNew York
LifeSci Venture PartnersreportedNew York
Venrock Healthcare Capital PartnersreportedNew York
Also in the syndicate · 5
Adage Capital Partners LPleadBoxer CapitalDAFNA Capital ManagementOctagon CapitalleadSuperstring Capitallead
Funding
SEC filings, press & company announcements$45.9M disclosed across 2 of 3 rounds · 2021–2024
- Undisclosed amountSeries A venture roundApr 2024
Adage Capital Partners LP (lead), Bain Capital Life Sciences (lead), Octagon Capital (lead), Superstring Capital (lead), Boxer Capital, Casdin Capital, DAFNA Capital Management, Venrock Healthcare Capital Partners
Source ↗
▶$42KraisedJan 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$42KraisedJan 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Chad A. CowanExecutive Officer, Director
- Martin MurphyDirector
- Daniel VasellaDirector
- Jim GlasheenExecutive Officer, Director
- Neil WhiteDirector
- Leandro VetcherExecutive Officer
- Offering amount
- $66K
- Amount sold
- $42K
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$45.9MraisedNov 2021 · 31 investors · PharmaceuticalsRule 506(b)
▶$45.9MraisedNov 2021 · 31 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Leandro VetcherExecutive Officer
- Daniel VasellaDirector
- Jim GlasheenExecutive Officer, Director
- Neil WhiteDirector
- Chad A. CowanExecutive Officer, Director
- Martin MurphyDirector
- Offering amount
- $87.1M
- Amount sold
- $45.9M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who founded Clade Therapeutics?
- Clade Therapeutics was founded by Chad A. Cowan in 2020.
- Who are Clade Therapeutics's investors?
- Clade Therapeutics's investors include Syncona, Bain Capital Life Sciences, Casdin Capital, LifeSci Venture Partners, Venrock Healthcare Capital Partners.
- How much funding has Clade Therapeutics raised?
- Clade Therapeutics has disclosed $45.9M raised across 2 of its 3 known rounds.
- Where is Clade Therapeutics headquartered?
- Clade Therapeutics is headquartered in Cambridge, US.